// App-Quantinova.ai

231 : Eribulin inhibits cell growth in cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft harboring TP53 and ARID2 mutations

Researchers

Presenter

  • C. Hsu

Principal Investigators

  • T. Yanagi

  • Maeda T.

  • H. Nishihara

  • K. Miyamoto

  • S. Kitamura

  • H. Ujiie

Medical Centers

  • Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Sapporo, Japan

  • Department of Dermatology, Hokkaido University faculty of medicine and graduate school of medicine, Sapporo, Hokkaido, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Cutaneous squamous cell carcinoma

Biomarkers

  • AT-rich interactive domain 2

  • Tumor protein p53

Drug/Treatment

  • Cisplatin

  • Eribulin

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved